Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 3, 2005, Pages 261-270

  Papazafiri, Panagiota ^a   Avlonitis, Nicolaos ^b   Angelou, Panagiotis ^b   Calogeropoulou, Theodora ^b   Koufaki, Maria ^b   Scoulica, Efi ^c   Fragiadaki, Irene ^c  

^a UNIVERSITY OF ATHENS   (Greece)

^b INSTITUTE OF BIOLOGY   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Anticancer; Ether phospholipids; Haemolysis; HePC

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CYCLOALKANE DERIVATIVE; DYE; ETHER PHOSPHOLIPID; MILTEFOSINE; PHOSPHATE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN; CELL STRAIN K 562; CELL STRAIN MCF 7; CELL STRAIN U937; CELLULAR DISTRIBUTION; CENTRIFUGATION; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG SUBSTITUTION; ERYTHROCYTE; HELA CELL; HEMOLYSIS; HUMAN; HUMAN CELL; HYDROGENATION; NONHUMAN; PRIORITY JOURNAL; REDUCTION; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; SUPERNATANT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOLYSIS; HUMANS; MALE; NEOPLASMS; PHOSPHOLIPID ETHERS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS;

EID: 21744460193     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0935-6     Document Type: Article

References (39)

1. Aroca JD, Sanchez-Pinera P, Corbalan-Garcia S, Conesa-Zamora P, deGodos A, Comez-Fernandez JC (2001) Correlation between the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine on the membrane and the activity of protein kinase Cα. Eur J Biochem 268:6369-6378
2. Arthur G, Bittman R (1998) The inhibition of cell signaling pathways by antitumor ether lipids. Biochim Biophys Acta 1390:85-102
3. Avlonitis N, Lekka E, Detsi A, Koufaki M, Calogeropoulou T, Scoulica E, Siapi E, Kyrikou I, Mavromoustakos T, Tsotinis A, Golic Grdadolnik S, Makriyannis A (2003) Antileishmanial ring-substituted ether phospholipids. J Med Chem 46:755-767
4. Berkovic D (1998) Cytotoxic etherphospholipid analogues. Gen Pharmacol 31:511-517
5. Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ (1997) Synergistic cytotoxic effects of ether phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol 43:293-301
6. Berkovic D, Berkovic K, Binder C, Haase D, Fleer EAM (2002) Hexadecylphosphocholine does not influence phospholipase D and sphingomyelinase activity in human leukemia cells. J Exp Ther Oncol 2:213-218
7. Brachwitz H, Vollgraf C (1995) Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells. Pharmacol Ther 66:39-82
8. Croft SL, Seifert K, Duchene M (2003) Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol 126:165-172
9. Crul M, Rosing H, deKlerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JHM, Beijnen JH, ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38:1615-1621
10. Eibl H, Kaufmann-Kolle P (1995) Medical application of synthetic phospholipids as liposomes and drugs. J Liposome Res 5:131
11. Erdlenbruch B, Jendrossek V, Gerriets A, Vetterlein F, Eibl H, Lakomek M (1999) Erucylphosphocholine:pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration. Cancer Chemother Pharmacol 44:484-490
12. Fleer EAM, Kim D-J, Nagel GA, Eibl H, Unger C (1990) Cytotoxic activity of lysophosphatidylcholine analogues on human lymphoma raji cells. Oncology 13:295
13. Gajate C, Santos-Beneit AM, Macho A, Lazaro MdC, Hernandez-De Rojas A, Modolell M, Munoz E, Mollinedo F (2000) Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. Int J Cancer 86:208-218
14. Gajate C, Fonteriz RI, Cabaner C, Alvares-Noves G, Alvarez-Rodriguez Y, Modolell M, Mollinedo F (2000) Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 85:674-682
15. 3), ilmofosine (BM 41.440) and the hexadecylphosphocholines D-20133 and D-21266 on histamine release from isolated rat mast cells. Immunopharmacology 44:211-221
16. Hanson PK, Malone L, Birchmore JL, Nichols JW (2003) Lemp3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine. J Biol Chem 278:36041-36050
17. Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher E, EIbl H, Unger C, Berger M (1988) Characterisation of the antitumor activity of hexadecylphosphocholine (D18506). Eur J Clin Oncol 24:1457
18. Jendorssek V, Erdlenbruch B, Hunold A, Kugler W, Eibl H, Lakomek M. (1999) Erucylphosphocholine, a novel antineoplastic ether lipid, blocks growth and induces apoptosis in brain tumor cell lines in vitro. Int J Oncol 14:15-22
19. Jendorssek V, Hammersen K, Erdlenbruch B, Kugler W, Krugener R, Eibl H, Lakomek M. (2002) Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother Pharmacol 50:71-79
20. Jendorssek V, Muller I, Eibl H, Belka C (2003) Intracellular mediators of erucylphosphocholine-induced apoptosis. Oncogene 22:2621
21. Kaufmann-Kolle P, Kotting J, Drevs J, Berger MR, Unger C, Eibl H (1992) Intravenous application of alkylphosphocholines:comparison of different homologues in lamellar structures. J Cancer Res Clin Oncol 120 [Supp 1]:R14
22. Kaufmann-Kolle P, Drevs J, Berger MR, Kotting J, Marschner N, Unger C, Eibl H (1994) Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother Pharmacol 34:393
23. Konstantinov SM, Eibl H, Berger MR (1998) Alkylphosphocholines induce apoptosis in HL-60 and U-937 leukemic cells. Cancer Cemother Pharmacol 41:210-216
24. Konstantinov SM, Topashka-Ancheva M, Benner A, Berger MR (1998) Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. Int J Cancer 77:778-786
25. Kotting J, Marschner NW, Neumuller W, Unger C, Eibl H (1992) Hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine: a comparison of haemolytic activity, serum binding and tissue distribution. In: Eibl H, Hilgard P, Unger C (eds) Alkylphosphocholines: new drugs in cancer therapy (Progress in experimental tumor research, vol 34). Karger-Verlag, Basel, p 131
26. Koufaki M, Polychroniou V, Calogeropoulou T, Tsotinis A, Drees M, Fiebig HH, LeClerc HR, Makriyannis A (1996) Alkyl and alkoxyethyl antineoplastic phospholipids. J Med Chem 39:2609-2614
27. 3. Biochem Biophys Res Commun 192:603-609
28. L. Cancer Res 57:1320-1328
29. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
30. Planting AST, Stoter G, Verweij J (1993) Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. Eur J Cancer 29a:518-519
31. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M (1999) Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59:2457-2463
32. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ (2001) Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 49:415-419
33. Rybczynska M, Spitaler M, Knebel NG, Boeck G, Grunicke H, Hofmann J (2001) Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem Pharmacol 62:765-772
34. Sobottka SB, Berger MR, Eibl H (1993) Structure-activity relationships of four anti-cancer alkylphosphocholine derivatives in vitro and in vivo. Int J Cancer 53:418
35. Spruss T, Bernhardt G, Schonenberger H, Engel J (1993) Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models. J Cancer Res Clin Oncol 19:142-149
36. Stekar J, Hilgard P, Klenner T (1995) Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer 3:372-374
37. Unger C, Eibl H (1991) Hexadecyl phosphocholine: preclinical and the first clinical results of a new antitumor drug. Lipids 26:1412-1417
38. Unger C, Damenz W, Fleer EAM, Kim DJ, Breiser A, Hilgard P, Engel J, Nagel G, Eibl H (1989) Hexadecylphosphocholine, a new ether lipid. Acta Oncol 28:213-217
39. Verweij J, Planting A, van der Burg M, Stoter GA (1992) A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118:606-608